Titre : Porphyrines

Porphyrines : Questions médicales fréquentes

Termes MeSH sélectionnés :

Early Detection of Cancer
{ "@context": "https://schema.org", "@graph": [ { "@type": "MedicalWebPage", "name": "Porphyrines : Questions médicales les plus fréquentes", "headline": "Porphyrines : Comprendre les symptômes, diagnostics et traitements", "description": "Guide complet et accessible sur les Porphyrines : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.", "datePublished": "2024-03-04", "dateModified": "2025-02-27", "inLanguage": "fr", "medicalAudience": [ { "@type": "MedicalAudience", "name": "Grand public", "audienceType": "Patient", "healthCondition": { "@type": "MedicalCondition", "name": "Porphyrines" }, "suggestedMinAge": 18, "suggestedGender": "unisex" }, { "@type": "MedicalAudience", "name": "Médecins", "audienceType": "Physician", "geographicArea": { "@type": "AdministrativeArea", "name": "France" } }, { "@type": "MedicalAudience", "name": "Chercheurs", "audienceType": "Researcher", "geographicArea": { "@type": "AdministrativeArea", "name": "International" } } ], "reviewedBy": { "@type": "Person", "name": "Dr Olivier Menir", "jobTitle": "Expert en Médecine", "description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale", "url": "/static/pages/docteur-olivier-menir.html", "alumniOf": { "@type": "EducationalOrganization", "name": "Université Paris Descartes" } }, "isPartOf": { "@type": "MedicalWebPage", "name": "Pigments biologiques", "url": "https://questionsmedicales.fr/mesh/D010860", "about": { "@type": "MedicalCondition", "name": "Pigments biologiques", "code": { "@type": "MedicalCode", "code": "D010860", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D23.767" } } }, "hasPart": [ { "@type": "MedicalWebPage", "name": "Coproporphyrines", "alternateName": "Coproporphyrins", "url": "https://questionsmedicales.fr/mesh/D003306", "about": { "@type": "MedicalCondition", "name": "Coproporphyrines", "code": { "@type": "MedicalCode", "code": "D003306", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D23.767.727.250" } } }, { "@type": "MedicalWebPage", "name": "Deutéroporphyrines", "alternateName": "Deuteroporphyrins", "url": "https://questionsmedicales.fr/mesh/D003905", "about": { "@type": "MedicalCondition", "name": "Deutéroporphyrines", "code": { "@type": "MedicalCode", "code": "D003905", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D23.767.727.280" } } }, { "@type": "MedicalWebPage", "name": "Étioporphyrines", "alternateName": "Etioporphyrins", "url": "https://questionsmedicales.fr/mesh/D005044", "about": { "@type": "MedicalCondition", "name": "Étioporphyrines", "code": { "@type": "MedicalCode", "code": "D005044", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D23.767.727.340" } } }, { "@type": "MedicalWebPage", "name": "Hématoporphyrines", "alternateName": "Hematoporphyrins", "url": "https://questionsmedicales.fr/mesh/D006415", "about": { "@type": "MedicalCondition", "name": "Hématoporphyrines", "code": { "@type": "MedicalCode", "code": "D006415", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D23.767.727.462" } }, "hasPart": [ { "@type": "MedicalWebPage", "name": "Hématoporphyrine D", "alternateName": "Hematoporphyrin Derivative", "url": "https://questionsmedicales.fr/mesh/D017324", "about": { "@type": "MedicalCondition", "name": "Hématoporphyrine D", "code": { "@type": "MedicalCode", "code": "D017324", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D23.767.727.462.400" } }, "hasPart": [ { "@type": "MedicalWebPage", "name": "Éther de dihématoporphyrine", "alternateName": "Dihematoporphyrin Ether", "url": "https://questionsmedicales.fr/mesh/D017323", "about": { "@type": "MedicalCondition", "name": "Éther de dihématoporphyrine", "code": { "@type": "MedicalCode", "code": "D017323", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D23.767.727.462.400.200" } } } ] }, { "@type": "MedicalWebPage", "name": "Éther de dihématoporphyrine", "alternateName": "Dihematoporphyrin Ether", "url": "https://questionsmedicales.fr/mesh/D017323", "about": { "@type": "MedicalCondition", "name": "Éther de dihématoporphyrine", "code": { "@type": "MedicalCode", "code": "D017323", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D23.767.727.462.400.200" } } } ] }, { "@type": "MedicalWebPage", "name": "Mésoporphyrines", "alternateName": "Mesoporphyrins", "url": "https://questionsmedicales.fr/mesh/D008652", "about": { "@type": "MedicalCondition", "name": "Mésoporphyrines", "code": { "@type": "MedicalCode", "code": "D008652", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D23.767.727.620" } } }, { "@type": "MedicalWebPage", "name": "Métalloporphyrines", "alternateName": "Metalloporphyrins", "url": "https://questionsmedicales.fr/mesh/D008665", "about": { "@type": "MedicalCondition", "name": "Métalloporphyrines", "code": { "@type": "MedicalCode", "code": "D008665", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D23.767.727.640" } }, "hasPart": [ { "@type": "MedicalWebPage", "name": "Hème", "alternateName": "Heme", "url": "https://questionsmedicales.fr/mesh/D006418", "about": { "@type": "MedicalCondition", "name": "Hème", "code": { "@type": "MedicalCode", "code": "D006418", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D23.767.727.640.587" } }, "hasPart": [ { "@type": "MedicalWebPage", "name": "Hémine", "alternateName": "Hemin", "url": "https://questionsmedicales.fr/mesh/D006427", "about": { "@type": "MedicalCondition", "name": "Hémine", "code": { "@type": "MedicalCode", "code": "D006427", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D23.767.727.640.587.462" } } } ] }, { "@type": "MedicalWebPage", "name": "Hémine", "alternateName": "Hemin", "url": "https://questionsmedicales.fr/mesh/D006427", "about": { "@type": "MedicalCondition", "name": "Hémine", "code": { "@type": "MedicalCode", "code": "D006427", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D23.767.727.640.587.462" } } } ] }, { "@type": "MedicalWebPage", "name": "Protoporphyrines", "alternateName": "Protoporphyrins", "url": "https://questionsmedicales.fr/mesh/D011524", "about": { "@type": "MedicalCondition", "name": "Protoporphyrines", "code": { "@type": "MedicalCode", "code": "D011524", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D23.767.727.725" } } }, { "@type": "MedicalWebPage", "name": "Uroporphyrines", "alternateName": "Uroporphyrins", "url": "https://questionsmedicales.fr/mesh/D014578", "about": { "@type": "MedicalCondition", "name": "Uroporphyrines", "code": { "@type": "MedicalCode", "code": "D014578", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D23.767.727.880" } } } ], "about": { "@type": "MedicalCondition", "name": "Porphyrines", "alternateName": "Porphyrins", "code": { "@type": "MedicalCode", "code": "D011166", "codingSystem": "MeSH" } }, "author": [ { "@type": "Person", "name": "Harry L Anderson", "url": "https://questionsmedicales.fr/author/Harry%20L%20Anderson", "affiliation": { "@type": "Organization", "name": "Department of Chemistry, University of Oxford, Chemistry Research Laboratory, OX1 3TA, Oxford, UK." } }, { "@type": "Person", "name": "Donato Monti", "url": "https://questionsmedicales.fr/author/Donato%20Monti", "affiliation": { "@type": "Organization", "name": "Department of Chemistry, Sapienza, University of Rome Piazzale Aldo Moro 5 00185 Rome Italy." } }, { "@type": "Person", "name": "Manuela Stefanelli", "url": "https://questionsmedicales.fr/author/Manuela%20Stefanelli", "affiliation": { "@type": "Organization", "name": "Department of Chemical Science and Technologies, University of Rome Tor Vergata via della Ricerca Scientifica 1 00133 Rome Italy gabriele.magna@uniroma2.it." } }, { "@type": "Person", "name": "Gabriele Magna", "url": "https://questionsmedicales.fr/author/Gabriele%20Magna", "affiliation": { "@type": "Organization", "name": "Department of Chemical Science and Technologies, University of Rome Tor Vergata via della Ricerca Scientifica 1 00133 Rome Italy gabriele.magna@uniroma2.it." } }, { "@type": "Person", "name": "Roberto Paolesse", "url": "https://questionsmedicales.fr/author/Roberto%20Paolesse", "affiliation": { "@type": "Organization", "name": "Department of Chemical Science and Technologies, University of Rome Tor Vergata via della Ricerca Scientifica 1 00133 Rome Italy gabriele.magna@uniroma2.it." } } ], "citation": [ { "@type": "ScholarlyArticle", "name": "Pathological and oncological outcomes of pylorus-preserving versus conventional distal gastrectomy in early gastric cancer: a systematic review and meta-analysis.", "datePublished": "2022-09-24", "url": "https://questionsmedicales.fr/article/36153587", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1186/s12957-022-02766-0" } }, { "@type": "ScholarlyArticle", "name": "Ornithine aminotransferase and carbamoyl phosphate synthetase 1 involved in ammonia metabolism serve as novel targets for early stages of gastric cancer.", "datePublished": "2022-09-13", "url": "https://questionsmedicales.fr/article/36098904", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1002/jcla.24692" } }, { "@type": "ScholarlyArticle", "name": "Patient characteristics and health system factors associated with adjuvant radiation therapy receipt in older women with early-stage endometrial cancer.", "datePublished": "2022-09-08", "url": "https://questionsmedicales.fr/article/36088216", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1016/j.jgo.2022.08.020" } }, { "@type": "ScholarlyArticle", "name": "Hybrid-control arm construction using historical trial data for an early-phase, randomized controlled trial in metastatic colorectal cancer.", "datePublished": "2022-07-15", "url": "https://questionsmedicales.fr/article/35856081", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1038/s43856-022-00155-y" } }, { "@type": "ScholarlyArticle", "name": "Early Mortality among Patients with Head and Neck Cancer Diagnosed in Thuringia, Germany, between 1996 and 2016-A Population-Based Study.", "datePublished": "2022-06-24", "url": "https://questionsmedicales.fr/article/35804871", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.3390/cancers14133099" } } ], "breadcrumb": { "@type": "BreadcrumbList", "itemListElement": [ { "@type": "ListItem", "position": 1, "name": "questionsmedicales.fr", "item": "https://questionsmedicales.fr" }, { "@type": "ListItem", "position": 2, "name": "Facteurs biologiques", "item": "https://questionsmedicales.fr/mesh/D001685" }, { "@type": "ListItem", "position": 3, "name": "Pigments biologiques", "item": "https://questionsmedicales.fr/mesh/D010860" }, { "@type": "ListItem", "position": 4, "name": "Porphyrines", "item": "https://questionsmedicales.fr/mesh/D011166" } ] } }, { "@type": "MedicalWebPage", "name": "Article complet : Porphyrines - Questions et réponses", "headline": "Questions et réponses médicales fréquentes sur Porphyrines", "description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.", "datePublished": "2025-05-08", "inLanguage": "fr", "hasPart": [ { "@type": "MedicalWebPage", "name": "Diagnostic", "headline": "Diagnostic sur Porphyrines", "description": "Comment diagnostiquer une porphyrie ?\nQuels tests sont utilisés pour les porphyrines ?\nQuels symptômes indiquent une porphyrie ?\nLes tests génétiques sont-ils nécessaires ?\nComment interpréter les résultats des tests ?", "url": "https://questionsmedicales.fr/mesh/D011166?mesh_terms=Early+Detection+of+Cancer&page=1000#section-diagnostic" }, { "@type": "MedicalWebPage", "name": "Symptômes", "headline": "Symptômes sur Porphyrines", "description": "Quels sont les symptômes courants des porphyries ?\nLes porphyries causent-elles des douleurs ?\nY a-t-il des symptômes cutanés ?\nLes porphyries affectent-elles le système nerveux ?\nLes symptômes varient-ils selon le type de porphyrie ?", "url": "https://questionsmedicales.fr/mesh/D011166?mesh_terms=Early+Detection+of+Cancer&page=1000#section-symptômes" }, { "@type": "MedicalWebPage", "name": "Prévention", "headline": "Prévention sur Porphyrines", "description": "Comment prévenir les crises de porphyrie ?\nY a-t-il des conseils diététiques pour les patients ?\nLes patients doivent-ils éviter certains médicaments ?\nLa gestion du stress est-elle importante ?\nLes patients doivent-ils être suivis régulièrement ?", "url": "https://questionsmedicales.fr/mesh/D011166?mesh_terms=Early+Detection+of+Cancer&page=1000#section-prévention" }, { "@type": "MedicalWebPage", "name": "Traitements", "headline": "Traitements sur Porphyrines", "description": "Quel est le traitement principal des porphyries ?\nLes transfusions sanguines sont-elles nécessaires ?\nY a-t-il des médicaments spécifiques pour les porphyries ?\nComment gérer les crises de porphyrie ?\nLa photoprotection est-elle recommandée ?", "url": "https://questionsmedicales.fr/mesh/D011166?mesh_terms=Early+Detection+of+Cancer&page=1000#section-traitements" }, { "@type": "MedicalWebPage", "name": "Complications", "headline": "Complications sur Porphyrines", "description": "Quelles sont les complications possibles des porphyries ?\nLes porphyries peuvent-elles causer des dommages au foie ?\nY a-t-il un risque accru de cancer ?\nLes complications neurologiques sont-elles fréquentes ?\nComment gérer les complications des porphyries ?", "url": "https://questionsmedicales.fr/mesh/D011166?mesh_terms=Early+Detection+of+Cancer&page=1000#section-complications" }, { "@type": "MedicalWebPage", "name": "Facteurs de risque", "headline": "Facteurs de risque sur Porphyrines", "description": "Quels sont les facteurs de risque des porphyries ?\nL'hérédité joue-t-elle un rôle ?\nLes femmes sont-elles plus à risque ?\nL'alcool augmente-t-il le risque ?\nLes infections peuvent-elles aggraver la condition ?", "url": "https://questionsmedicales.fr/mesh/D011166?mesh_terms=Early+Detection+of+Cancer&page=1000#section-facteurs de risque" } ] }, { "@type": "FAQPage", "mainEntity": [ { "@type": "Question", "name": "Comment diagnostiquer une porphyrie ?", "position": 1, "acceptedAnswer": { "@type": "Answer", "text": "Le diagnostic repose sur des tests sanguins et urinaires pour mesurer les niveaux de porphyrines." } }, { "@type": "Question", "name": "Quels tests sont utilisés pour les porphyrines ?", "position": 2, "acceptedAnswer": { "@type": "Answer", "text": "Les tests incluent l'analyse des urines, du sang et parfois des biopsies de peau." } }, { "@type": "Question", "name": "Quels symptômes indiquent une porphyrie ?", "position": 3, "acceptedAnswer": { "@type": "Answer", "text": "Les symptômes peuvent inclure des douleurs abdominales, des troubles neurologiques et des photosensibilités." } }, { "@type": "Question", "name": "Les tests génétiques sont-ils nécessaires ?", "position": 4, "acceptedAnswer": { "@type": "Answer", "text": "Oui, des tests génétiques peuvent aider à confirmer certains types de porphyries héréditaires." } }, { "@type": "Question", "name": "Comment interpréter les résultats des tests ?", "position": 5, "acceptedAnswer": { "@type": "Answer", "text": "Des niveaux élevés de porphyrines dans le sang ou l'urine indiquent une porphyrie." } }, { "@type": "Question", "name": "Quels sont les symptômes courants des porphyries ?", "position": 6, "acceptedAnswer": { "@type": "Answer", "text": "Les symptômes incluent des douleurs abdominales, des éruptions cutanées et des troubles mentaux." } }, { "@type": "Question", "name": "Les porphyries causent-elles des douleurs ?", "position": 7, "acceptedAnswer": { "@type": "Answer", "text": "Oui, des douleurs abdominales aiguës sont fréquentes lors des crises de porphyrie." } }, { "@type": "Question", "name": "Y a-t-il des symptômes cutanés ?", "position": 8, "acceptedAnswer": { "@type": "Answer", "text": "Oui, des éruptions cutanées et une photosensibilité peuvent survenir, surtout dans la porphyrie cutanée." } }, { "@type": "Question", "name": "Les porphyries affectent-elles le système nerveux ?", "position": 9, "acceptedAnswer": { "@type": "Answer", "text": "Oui, elles peuvent provoquer des troubles neurologiques, y compris des crises et des hallucinations." } }, { "@type": "Question", "name": "Les symptômes varient-ils selon le type de porphyrie ?", "position": 10, "acceptedAnswer": { "@type": "Answer", "text": "Oui, chaque type de porphyrie présente des symptômes spécifiques et des manifestations cliniques." } }, { "@type": "Question", "name": "Comment prévenir les crises de porphyrie ?", "position": 11, "acceptedAnswer": { "@type": "Answer", "text": "Éviter les déclencheurs comme certains médicaments, l'alcool et le stress peut aider." } }, { "@type": "Question", "name": "Y a-t-il des conseils diététiques pour les patients ?", "position": 12, "acceptedAnswer": { "@type": "Answer", "text": "Une alimentation équilibrée et riche en glucides peut aider à prévenir les crises." } }, { "@type": "Question", "name": "Les patients doivent-ils éviter certains médicaments ?", "position": 13, "acceptedAnswer": { "@type": "Answer", "text": "Oui, certains médicaments peuvent déclencher des crises et doivent être évités." } }, { "@type": "Question", "name": "La gestion du stress est-elle importante ?", "position": 14, "acceptedAnswer": { "@type": "Answer", "text": "Oui, la gestion du stress est cruciale pour prévenir les crises de porphyrie." } }, { "@type": "Question", "name": "Les patients doivent-ils être suivis régulièrement ?", "position": 15, "acceptedAnswer": { "@type": "Answer", "text": "Oui, un suivi médical régulier est essentiel pour surveiller l'évolution de la maladie." } }, { "@type": "Question", "name": "Quel est le traitement principal des porphyries ?", "position": 16, "acceptedAnswer": { "@type": "Answer", "text": "Le traitement principal inclut l'évitement des déclencheurs et des médicaments pour soulager les symptômes." } }, { "@type": "Question", "name": "Les transfusions sanguines sont-elles nécessaires ?", "position": 17, "acceptedAnswer": { "@type": "Answer", "text": "Dans certains cas, des transfusions peuvent être nécessaires pour traiter l'anémie associée." } }, { "@type": "Question", "name": "Y a-t-il des médicaments spécifiques pour les porphyries ?", "position": 18, "acceptedAnswer": { "@type": "Answer", "text": "Des médicaments comme l'hématine peuvent être utilisés pour traiter les crises aiguës de porphyrie." } }, { "@type": "Question", "name": "Comment gérer les crises de porphyrie ?", "position": 19, "acceptedAnswer": { "@type": "Answer", "text": "Les crises peuvent être gérées par des soins d'urgence et des traitements symptomatiques." } }, { "@type": "Question", "name": "La photoprotection est-elle recommandée ?", "position": 20, "acceptedAnswer": { "@type": "Answer", "text": "Oui, les patients doivent éviter l'exposition au soleil et utiliser des écrans solaires." } }, { "@type": "Question", "name": "Quelles sont les complications possibles des porphyries ?", "position": 21, "acceptedAnswer": { "@type": "Answer", "text": "Les complications incluent des lésions nerveuses, des problèmes hépatiques et des infections." } }, { "@type": "Question", "name": "Les porphyries peuvent-elles causer des dommages au foie ?", "position": 22, "acceptedAnswer": { "@type": "Answer", "text": "Oui, certaines porphyries peuvent entraîner des lésions hépatiques graves." } }, { "@type": "Question", "name": "Y a-t-il un risque accru de cancer ?", "position": 23, "acceptedAnswer": { "@type": "Answer", "text": "Certaines porphyries, comme la porphyrie cutanée, peuvent augmenter le risque de cancer de la peau." } }, { "@type": "Question", "name": "Les complications neurologiques sont-elles fréquentes ?", "position": 24, "acceptedAnswer": { "@type": "Answer", "text": "Oui, des complications neurologiques peuvent survenir, affectant la qualité de vie." } }, { "@type": "Question", "name": "Comment gérer les complications des porphyries ?", "position": 25, "acceptedAnswer": { "@type": "Answer", "text": "La gestion des complications nécessite un suivi médical et des traitements adaptés." } }, { "@type": "Question", "name": "Quels sont les facteurs de risque des porphyries ?", "position": 26, "acceptedAnswer": { "@type": "Answer", "text": "Les facteurs incluent des antécédents familiaux, certains médicaments et des conditions hépatiques." } }, { "@type": "Question", "name": "L'hérédité joue-t-elle un rôle ?", "position": 27, "acceptedAnswer": { "@type": "Answer", "text": "Oui, certaines porphyries sont héréditaires et peuvent être transmises dans les familles." } }, { "@type": "Question", "name": "Les femmes sont-elles plus à risque ?", "position": 28, "acceptedAnswer": { "@type": "Answer", "text": "Certaines études montrent que les femmes peuvent être plus touchées par certaines porphyries." } }, { "@type": "Question", "name": "L'alcool augmente-t-il le risque ?", "position": 29, "acceptedAnswer": { "@type": "Answer", "text": "Oui, la consommation d'alcool peut déclencher des crises chez les personnes prédisposées." } }, { "@type": "Question", "name": "Les infections peuvent-elles aggraver la condition ?", "position": 30, "acceptedAnswer": { "@type": "Answer", "text": "Oui, certaines infections peuvent exacerber les symptômes des porphyries." } } ] } ] }

Sources (10000 au total)

Pathological and oncological outcomes of pylorus-preserving versus conventional distal gastrectomy in early gastric cancer: a systematic review and meta-analysis.

Pylorus-preserving gastrectomy (PPG) is a function-preserving surgery for the treatment of early gastric cancer (EGC) in the middle third of the stomach. According to the literature reports, PPG decre... The protocol was registered in PROSPERO under number CRD42022304677. Databases including PubMed, Embase, Web of Science, and the Cochrane Register of Controlled Trials were searched before February 21... A total of 4500 patients from 16 studies were included. Compared with the CDG group, the PPG group had fewer lymph nodes harvested (WMD= -3.09; 95% CI -4.75 to -1.43; P < 0.001). Differences in the nu... The meta-analysis of existing evidence demonstrated that the survival outcomes of PPG may be comparable to those of CDG. However, fewer lymph nodes at stations in No. 5, No. 6, No. 9, and No. 11p were...

Ornithine aminotransferase and carbamoyl phosphate synthetase 1 involved in ammonia metabolism serve as novel targets for early stages of gastric cancer.

The sensitivity and specificity of current biomarkers for gastric cancer were insufficient. The aim of the present study was to screen novel biomarkers and determine the diagnostic values of ornithine... With stable isotope tags, we labelled an initial discovery group of four paired gastric cancer tissue samples and identified with LC-ESI-MS/MS. A validation group of 159 gastric cancer samples and 30 ... Four hundred and thirty one proteins were found differentially expressed in gastric cancer tissues. Of these proteins, OAT and CPS1 were found over-expressed in gastric cancer patients, with sensitivi... The present findings indicated a tight correlation between the co-expression of OAT and CPS1 and the histological grade, local invasion, and TNM stages of gastric cancer. Therefore, OAT and CPS1 might...

Patient characteristics and health system factors associated with adjuvant radiation therapy receipt in older women with early-stage endometrial cancer.

Among women with early-stage endometrial cancer (EC), age, stage, grade, and histology are used to determine fitness for adjuvant radiation therapy (RT) administration. We examined non-cancer factors ... Using data from the Surveillance Epidemiology and End Results cancer registry program linked with Medicare claims, we identified 25,654 women (aged ≥66 years) diagnosed with first primary stage I-II E... Adjuvant RT was less commonly administered to Asian American and Pacific Islander patients than non-Hispanic White patients (Prevalence ratio [PR], 0.84; 95% confidence interval [CI], 0.73 to 0.97). C... Findings suggest that various non-cancer factors affect the delivery of adjuvant RT to older women with early-stage EC in real-world oncology practice. Advancing our understanding of factors associate...

Hybrid-control arm construction using historical trial data for an early-phase, randomized controlled trial in metastatic colorectal cancer.

Treatment for metastatic colorectal cancer patients beyond the second line remains challenging, highlighting the need for early phase trials of combination therapies for patients who had disease progr... MORPHEUS-CRC is an umbrella, multicenter, open-label, phase Ib/II, randomized, controlled trial (NCT03555149), with active experimental arms ongoing. Patients enrolled were assigned to a control arm (... The experimental arm showed no efficacy signal, yet a well-tolerated safety profile in the MORPHEUS-CRC trial. Treatment effects estimated in hybrid control design were comparable to those in the MORP... Hybrid control provides comparable treatment-effect estimates with generally improved precision, and thus can be of value to inform early-phase clinical development in metastatic colorectal cancer....

Construction and validation of N6-methyladenosine long non-coding RNAs signature of prognostic value for early biochemical recurrence of prostate cancer.

Early biochemical recurrence (eBCR) indicated a high risk for potential recurrence and metastasis in prostate cancer. The N6-methyladenosine (m6A) methylation modification played an important role in ... Pearson correlation analysis was first conducted to explore m6A lncRNAs and univariate Cox regression analysis was further performed to identify m6A lncRNAs of prognostic roles for predicting eBCR in ... Five hundred and thirty-eighth m6A lncRNAs were searched out through Pearson correlation analysis and 25 out of 538 m6A lncRNAs were identified to pose prediction roles for eBCR in prostate cancers. A... The m6A lncRNA signature in this study could be utilized to efficiently predict eBCR occurrence, various clinical characteristic and immune microenvironment for prostate cancer....

MRI characteristics of breast edema for assessing axillary lymph node burden in early-stage breast cancer: a retrospective bicentric study.

To investigate whether breast edema characteristics at preoperative T2-weighted imaging (T2WI) could help evaluate axillary lymph node (ALN) burden in patients with early-stage breast cancer.... This retrospective study included women with clinical T1 and T2 stage breast cancer and preoperative MRI examination in two independent cohorts from May 2014 to December 2020. Low (< 3 LNs+) and high ... A total of 1092 patients were included in this study. BES was identified as the independent predictor of pALN burden in primary (n = 677) and validation (n = 415) cohorts. The analysis using MRI-ALN s... In individuals with early-stage breast cancer, preoperative MRI characteristics of breast edema could be a promising predictor for pALN burden, which may aid in treatment planning.... • In this retrospective study of 1092 patients with early-stage breast cancer from two cohorts, the MRI characteristic of breast edema has independent and additive predictive value for assessing axill...

A Clinical Diagnostic Value Analysis of Serum CA125, CA199, and HE4 in Women with Early Ovarian Cancer: Systematic Review and Meta-Analysis.

To evaluate the value of combined detection of serum CA125, CA199, and HE4 in the diagnosis of ovarian cancer.... Relevant articles retrieved from PubMed, Elsevier Science, Springer, China National Knowledge Infrastructure (CNKI), Wanfang, and VIP databases were screened strictly according to inclusion and exclus... The results of meta-analysis showed that there was a statistical difference in diagnostic specificity analysis of CA125 (OR = 1.91, 95% CI (1.58, 2.32),... In the clinical assisted diagnosis of ovarian cancer, combined detection of CA125, CA199, and HE4 has the stronger discriminant ability and higher accuracy than single detection of CA125, which can im...

BMI increase during early childhood in boys with cystic fibrosis and early adrenarche.

Increase in body mass index (BMI) in early childhood (1-6 years) was found to be a contributing factor for impaired final height in boys with Cystic Fibrosis (CF). Early adrenarche (before age 9 years... Boys with CF, aged 8-9 years, visiting the CF expertize center Utrecht were included. Since 2018, anthropomorphic, pubertal and endocrine data were collected. Early adrenarche in boys was defined as a... Thirteen boys (mean age 8.55 ± 0.27 years) were enrolled. The median (IQR) DHEAS-level was 1.3 µmol/L (0.71-2.40). Eight boys (61.5%) had an early rise in DHEAS-levels ≥ 1 µmol/L. Mean increase in BMI... In this small cohort, 61.5% of boys with CF between 8 and 9 years had an early rise of DHEAS, which was correlated to ΔBMI...